Tech Company Financing Transactions
Allogene Therapeutics Funding Round
Perceptive Advisors, Deerfield Capital and Fidelity Management & Research Company joined a $120 million funding round for Allogene Therapeutics. The financing round was announced on 9/10/2018.
Transaction Overview
Company Name
Announced On
9/10/2018
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This financing will help us accelerate the development of our broad portfolio and invest in world class technical operations to make potentially lifesaving cell therapies more readily accessible to patients.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
210 E Grand Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Arie Belldegrun
Chief Executive Officer
David Chang
Chief Financial Officer
Eric Schmidt
Chief Scientific Officer
Barbra Sasu
Chief Technical Officer
Alison Moore
Vice President
David Tillett
VP - Bus. Development
Susie Jun
VP - General Counsel
Veer Bhavnagri
Browse more venture capital transactions:
Prev: 9/10/2018: Pika Energy venture capital transaction
Next: 9/10/2018: Sonatype venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs